KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Long-Term Investments: 2018-2019

Historic Long-Term Investments for Esperion Therapeutics (ESPR) over the last 1 years, with Mar 2019 value amounting to $30.9 million.

  • Esperion Therapeutics' Long-Term Investments fell 27.05% to $30.9 million in Q1 2019 from the same period last year, while for Mar 2019 it was $30.9 million, marking a year-over-year decrease of 27.05%. This contributed to the annual value of $243,000 for FY2018, which is N/A change from last year.
  • Per Esperion Therapeutics' latest filing, its Long-Term Investments stood at $30.9 million for Q1 2019, which was up 12,614.40% from $243,000 recorded in Q4 2018.
  • In the past 5 years, Esperion Therapeutics' Long-Term Investments registered a high of $42.4 million during Q1 2018, and its lowest value of $243,000 during Q4 2018.
  • Over the past 2 years, Esperion Therapeutics' median Long-Term Investments value was $21.6 million (recorded in 2018), while the average stood at $20.1 million.
  • Data for Esperion Therapeutics' Long-Term Investments shows a maximum YoY fell of 27.05% (in 2019) over the last 5 years.
  • Quarterly analysis of 2 years shows Esperion Therapeutics' Long-Term Investments stood at $243,000 in 2018, then declined by 27.05% to $30.9 million in 2019.
  • Its Long-Term Investments was $30.9 million in Q1 2019, compared to $243,000 in Q4 2018 and $5.2 million in Q3 2018.